Larotrectinib treatment resulted in rapid and durable tumor regression and allowed for limb-sparing surgeries in patients who otherwise would have undergone amputations, confirming larotrectinib as a promising therapy for ETV6-NTRK3 fusion-positive IFS (DuBois et al., 2018). Here, NTRK3 is linked to neoplasm.